Tilray's Stock Is Down 45% This Year, and Here's Why It Could Still Go Lower

Tilray stock is down 45% year to date in 2026, and the article argues it could fall further as Trulieve uplisted to the NYSE, giving investors a more direct way to access the U.S. marijuana market. The U.S. rescheduling of certain medical marijuana products to Schedule III enabled Trulieve's exchange listing, reducing Tilray's appeal as a proxy for U.S. cannabis exposure. Tilray has also posted operating losses in each of the past four quarters and lacks consistent growth.

Analysis

The key market shift is not the uplist itself, but the removal of Tilray as the default public-market proxy for U.S. cannabis optionality. That matters because speculative capital tends to cluster around the cleanest listed expression of a theme; once a more direct U.S.-exposed vehicle is available on a major exchange, the “story premium” migrates quickly and the weaker balance sheet / weaker operating leverage name gets de-rated first. In practice, this is a positioning and flow problem before it is a fundamentals problem.

Tilray’s secondary weakness is that its diversification away from cannabis does not create a comparable scarcity value. Beverage/craft exposure may smooth reported revenue, but it also anchors the stock to lower-multiple consumer categories while the market is asking for a cannabis beta trade. That creates a bad mix: investors pay for a call option on U.S. legalization, but the underlying business behaves like a slow-growth, capital-consuming roll-up. If U.S. policy headlines continue to improve, the market is likely to award the incremental multiple expansion to the name with direct U.S. operating leverage, not to the diversified laggard.

The contrarian risk is that the move could overshoot in the near term if retail traders use the new NYSE listing as a liquidity event and pile into Trulieve, leaving Tilray temporarily dislocated on the downside. But over a 3-6 month horizon, the more durable pressure is that TLRY loses its relative relevance in cannabis baskets and thematic screens. The big reversal catalyst for TLRY would be a meaningful U.S. federal reform pathway that opens institutional demand broadly across the sector; absent that, the stock is vulnerable to repeated valuation compression whenever capital rotates toward cleaner U.S. exposure.

Key Decisions for Investors

• Short TLRY on any post-uplist sector-strength bounce; target 1-3 months with a 15-25% downside window as the market re-rates away from the legacy proxy.
• Long TRLV as the cleaner U.S. cannabis beta; use a 3-6 month horizon and size for high volatility, with upside tied to sustained flows from investors seeking direct U.S. exposure.
• Pair trade: long TRLV / short TLRY to isolate relative theme migration; highest expected value if sector sentiment improves but broad cannabis fundamentals remain weak.
• For options traders, buy TLRY put spreads 2-4 months out to express continued de-rating while capping premium burn; thesis breaks if federal reform materially broadens the investable universe.
• Avoid treating TLRY as the default cannabis basket hedge; if you need sector exposure, rotate toward the most direct U.S. operating leverage rather than the weakest balance-sheet proxy.